
X
Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof
https://pharmaphorum.com/news/phase-3-wins-put-dermavant-closer-to-filing-otezla-rival-tapinarof/
Biotech entrepreneur hopes to bounce back from Alzheimer’s disappointment
Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.